The Steady Ascent of Aurora Spine: Is a Surge Coming?

Intro

Aurora Spine recently reported its 2024 year-end results and subsequently its 2025 Q1 results. I want to jot down my impressions. Additionally, I will share some in-depth insights from a recent interview with CEO Trent Northcutt and conversations with the company's representatives. There will be a special focus on the sales arm of the company, which will be a strong determining factor in future success.

The full article is available exclusively to our paid subscribers, to whom we are deeply grateful for their continued financial support over the past few months.

Revenue Growth

Though I love profitability, the first number to look at is revenue. The revenue growth for Q1 was 13%. I would be much happier with 25% to 35% year-over-year (YoY) growth—a percentage target I had for many years before the 2019 pandemic. Aurora is well-positioned to be a disruptive force due to its strong product lineup.

The whole-year growth for 2024 was 21%, which is a better number. Much of that was built on the success of a newly launched SiLO-TFX. Without a new product launch, that year-over-year growth is harder to achieve. I don’t care that Q4 and Q1 are the weakest quarters - the YoY growth for those quarters wasn’t what I was hoping for.

So where is this train headed? What are we going to see for 2025 and 2026 for Aurora Spine, the company? I don’t have a crystal ball, but I’m going to give you my best effort prediction.